ClinicalTrials.gg
CompletedNCT07086079Updated Feb 20, 2026

A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

A Phase 1 interventional study of DOR/ISL in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this study is to learn what happens to doravirine (DOR) and islatravir (ISL) in a healthy lactating female's body over time. Researchers want to learn if DOR and ISL are in breast milk.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Is at least 6-weeks postpartum at the time of administration of study drug, following the delivery of a healthy singleton neonate
  • Is willing and able to express breast milk using an electric pump prior to study drug administration and is expected to be able to express at least 4 times over a 24-hour period after study drug administration

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, psychiatric, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has had mastitis within 30 days prior to administration of study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    DOR/ISL

    Participants will receive DOR/ISL as an oral fixed-dose combination tablet once daily on Days 1 to 7.

    Drug: DOR/ISL

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative Amount of DOR Excreted in Breast Milk From 0 to 24 Hours (Ae0-24hrs)

    Breast milk samples will be collected to determine the Ae0-24hrs after administration of DOR.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  2. Body Weight Normalized Infant Theoretical Dose of DOR

    Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of DOR as normalized by participant-reported infant body weight.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  3. Relative Infant Theoretical Dose of DOR

    Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of DOR relative to the maternal dose.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  4. Cumulative Amount of Total ISL Excreted in Breast Milk From 0 to 24 Hours (Ae0-24hrs)

    Breast milk samples will be collected to determine the Ae0-24hrs after administration of total ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  5. Body Weight Normalized Infant Theoretical Dose of ISL

    Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of ISL as normalized by participant-reported infant body weight.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  6. Relative Infant Theoretical Dose of ISL

    Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of ISL relative to the maternal dose.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

Secondary outcomes

  1. Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24hrs) of DOR in Breast Milk

    Breast milk samples will be collected to determine the AUC0-24hrs of DOR.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  2. Maximum Concentration (Cmax) of DOR in Breast Milk

    Breast milk samples will be collected to determine the Cmax of DOR.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  3. Time to Maximum Concentration (Tmax) of DOR in Breast Milk

    Breast milk samples will be collected to determine the Tmax of DOR

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  4. AUC0-24hrs of Total ISL in Breast Milk

    Breast milk samples will be collected to determine the AUC0-24hrs of total ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  5. Cmax of Total ISL in Breast Milk

    Breast milk samples will be collected to determine the Cmax of total ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  6. Tmax of Total ISL in Breast Milk

    Breast milk samples will be collected to determine the Tmax of total ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  7. AUC0-24hrs of DOR in Plasma

    Plasma samples will be collected to determine the AUC0-24hrs of DOR.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  8. Cmax of DOR in Plasma

    Plasma samples will be collected to determine the Cmax of DOR.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  9. Tmax of DOR in Plasma

    Plasma samples will be collected to determine the Tmax of DOR.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  10. Concentration at 24 Hours (C24) of DOR in Plasma

    Plasma samples will be collected to determine the C24 of DOR.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  11. AUC0-24hrs of ISL in Plasma

    Plasma samples will be collected to determine the AUC0-24hrs of ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  12. Cmax of ISL in Plasma

    Plasma samples will be collected to determine the Cmax of ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  13. Tmax of ISL in Plasma

    Plasma samples will be collected to determine the Tmax of ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  14. C24 of ISL in Plasma

    Plasma samples will be collected to determine the C24 of ISL.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

07

Study locations

1 site
  • QPS Missouri ( Site 0001)
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Dec 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Jul 25, 2025
StartActual
Sep 26, 2025
Primary completionActual
Dec 8, 2025
CompletionActual
Feb 4, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07086079
Responsible party
Sponsor
First posted
Jul 25, 2025
Start date
Sep 26, 2025
Primary completion
Dec 8, 2025
Completion
Feb 4, 2026
Last update
Feb 20, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion